Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.

Spunarova M, Tom N, Pavlova S, Mraz M, Brychtova Y, Doubek M, Panovska A, Skuhrova Francova H, Brzobohata A, Pospisilova S, Mayer J, Trbusek M.

Leuk Res. 2019 Jun;81:75-81. doi: 10.1016/j.leukres.2019.04.015. Epub 2019 Apr 25.

PMID:
31054420
2.

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.

Boudny M, Zemanova J, Khirsariya P, Borsky M, Verner J, Cerna J, Oltova A, Seda V, Mraz M, Jaros J, Jaskova Z, Spunarova M, Brychtova Y, Soucek K, Drapela S, Kasparkova M, Mayer J, Paruch K, Trbusek M.

Haematologica. 2019 Apr 11. pii: haematol.2018.203430. doi: 10.3324/haematol.2018.203430. [Epub ahead of print]

3.

MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.

Cerna K, Oppelt J, Chochola V, Musilova K, Seda V, Pavlasova G, Radova L, Arigoni M, Calogero RA, Benes V, Trbusek M, Brychtova Y, Doubek M, Mayer J, Pospisilova S, Mraz M.

Leukemia. 2019 Feb;33(2):403-414. doi: 10.1038/s41375-018-0230-x. Epub 2018 Aug 15.

PMID:
30111844
4.

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.

Pavlasova G, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J, Seda V, Fojtova M, Fajkus J, Brychtova Y, Doubek M, Pospisilova S, Mayer J, Mraz M.

Leukemia. 2018 Sep;32(9):2028-2031. doi: 10.1038/s41375-018-0211-0. Epub 2018 Jul 20. No abstract available.

PMID:
30030508
5.

Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL.

Brazdilova K, Plevova K, Skuhrova Francova H, Kockova H, Borsky M, Bikos V, Malcikova J, Oltova A, Kotaskova J, Tichy B, Brychtova Y, Mayer J, Doubek M, Pospisilova S.

Leukemia. 2018 Jan;32(1):234-236. doi: 10.1038/leu.2017.274. Epub 2017 Aug 29. No abstract available.

6.

Fragment analysis represents a suitable approach for the detection of hotspot c.7541_7542delCT NOTCH1 mutation in chronic lymphocytic leukemia.

Vavrova E, Kantorova B, Vonkova B, Kabathova J, Skuhrova-Francova H, Diviskova E, Letocha O, Kotaskova J, Brychtova Y, Doubek M, Mayer J, Pospisilova S.

Leuk Res. 2017 Sep;60:145-150. doi: 10.1016/j.leukres.2017.08.001. Epub 2017 Aug 7.

PMID:
28837890
7.

Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV.

Poppova L, Janovska P, Plevova K, Radova L, Plesingerova H, Borsky M, Kotaskova J, Kantorova B, Hlozkova M, Figulova J, Brychtova Y, Machalova M, Urik M, Doubek M, Kozubik A, Pospisilova S, Pavlova S, Bryja V.

Br J Haematol. 2016 Dec;175(5):851-859. doi: 10.1111/bjh.14312. Epub 2016 Sep 21.

PMID:
27651098
8.

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.

Zemanova J, Hylse O, Collakova J, Vesely P, Oltova A, Borsky M, Zaprazna K, Kasparkova M, Janovska P, Verner J, Kohoutek J, Dzimkova M, Bryja V, Jaskova Z, Brychtova Y, Paruch K, Trbusek M.

Oncotarget. 2016 Sep 20;7(38):62091-62106. doi: 10.18632/oncotarget.11388.

9.

Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients.

Kantorova B, Malcikova J, Brazdilova K, Borsky M, Plevova K, Smardova J, Radova L, Tom N, Trbusek M, Diviskova E, Francova HS, Navrkalova V, Doubek M, Brychtova Y, Mayer J, Pospisilova S.

Br J Haematol. 2017 Sep;178(6):979-982. doi: 10.1111/bjh.14176. Epub 2016 Jul 29. No abstract available.

PMID:
27470445
10.

ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells.

Kotašková J, Pavlová Š, Greif I, Stehlíková O, Plevová K, Janovská P, Brychtová Y, Doubek M, Pospíšilová Š, Bryja V.

Br J Haematol. 2016 Oct;175(2):339-342. doi: 10.1111/bjh.13848. Epub 2015 Nov 16. No abstract available.

PMID:
26567475
11.

Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia.

Janovska P, Poppova L, Plevova K, Plesingerova H, Behal M, Kaucka M, Ovesna P, Hlozkova M, Borsky M, Stehlikova O, Brychtova Y, Doubek M, Machalova M, Baskar S, Kozubik A, Pospisilova S, Pavlova S, Bryja V.

Clin Cancer Res. 2016 Jan 15;22(2):459-69. doi: 10.1158/1078-0432.CCR-15-0154. Epub 2015 Aug 3.

12.

Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide.

Schwarz J, Ovesná P, Černá O, Kissová J, Maaloufová Soukupová J, Brychtová Y, Doubek M, Červinek L, Cmunt E, Dulíček P, Campr V, Křen L, Penka M; CZEMP-Czech Group for Ph- Myeloproliferative Disorders.

Eur J Haematol. 2016 Jan;96(1):98-106. doi: 10.1111/ejh.12554. Epub 2015 Apr 21.

PMID:
25807961
13.

Analysis of prognostic significance of merkel cell polyomavirus in chronic lymphocytic leukemia.

Trizuljak J, Srovnal J, Plevová K, Brychtová Y, Semerád L, Bakešová D, Létalová E, Benedíková A, Mayer J, Hajdúch M, Pospíšilová Š, Doubek M.

Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):439-42. doi: 10.1016/j.clml.2015.02.003. Epub 2015 Feb 11.

PMID:
25758600
14.

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.

Doubek M, Brychtova Y, Panovska A, Sebejova L, Stehlikova O, Chovancova J, Malcikova J, Smardova J, Plevova K, Volfova P, Trbusek M, Mraz M, Bakesova D, Trizuljak J, Hadrabova M, Obrtlikova P, Karban J, Smolej L, Oltova A, Jelinkova E, Pospisilova S, Mayer J.

Am J Hematol. 2015 May;90(5):417-21. doi: 10.1002/ajh.23964. Epub 2015 Apr 1.

15.

TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.

Kantorova B, Malcikova J, Smardova J, Pavlova S, Trbusek M, Tom N, Plevova K, Tichy B, Truong S, Diviskova E, Kotaskova J, Oltova A, Patten N, Brychtova Y, Doubek M, Mayer J, Pospisilova S.

Tumour Biol. 2015 May;36(5):3371-80. doi: 10.1007/s13277-014-2971-0. Epub 2014 Dec 20.

PMID:
25527155
16.

[Differential diagnostics of hypereosinophilia].

Doubek M, Brychtová Y, Kissová J, Tomíška M, Adam Z.

Vnitr Lek. 2014;60 Suppl 2:21-7. Czech.

PMID:
25389091
17.

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.

Malcikova J, Stano-Kozubik K, Tichy B, Kantorova B, Pavlova S, Tom N, Radova L, Smardova J, Pardy F, Doubek M, Brychtova Y, Mraz M, Plevova K, Diviskova E, Oltova A, Mayer J, Pospisilova S, Trbusek M.

Leukemia. 2015 Apr;29(4):877-85. doi: 10.1038/leu.2014.297. Epub 2014 Oct 28.

18.

Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia.

Kminkova J, Mraz M, Zaprazna K, Navrkalova V, Tichy B, Plevova K, Malcikova J, Cerna K, Rausch T, Benes V, Brychtova Y, Doubek M, Mayer J, Pospisilova S.

Carcinogenesis. 2014 May;35(5):992-1002. doi: 10.1093/carcin/bgt396. Epub 2013 Dec 4.

19.

Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.

Fiegl M, Stauder R, Steurer M, Mian M, Hopfinger G, Brychtova Y, Skrabs C, Zabernigg A, Schmid F, Haslbaur F, Winder G, Walder A, Lang A, Voskova D, Greil R, Mayer J, Gastl G; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL.

Ann Hematol. 2014 Feb;93(2):267-77. doi: 10.1007/s00277-013-1966-z. Epub 2013 Nov 30.

PMID:
24292560
20.

Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis.

Brejcha M, Stoklasová M, Brychtová Y, Panovská A, Štěpanovská K, Vaňková G, Plevová K, Oltová A, Horká K, Pospíšilová Š, Mayer J, Doubek M.

Leuk Res. 2014 Feb;38(2):170-5. doi: 10.1016/j.leukres.2013.10.019. Epub 2013 Oct 29.

PMID:
24246692
21.

Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones.

Plevova K, Francova HS, Burckova K, Brychtova Y, Doubek M, Pavlova S, Malcikova J, Mayer J, Tichy B, Pospisilova S.

Haematologica. 2014 Feb;99(2):329-38. doi: 10.3324/haematol.2013.087593. Epub 2013 Sep 13.

22.

Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.

Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M.

Int J Lab Hematol. 2014 Apr;36(2):165-71. doi: 10.1111/ijlh.12149. Epub 2013 Sep 13.

PMID:
24028768
23.

Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.

Krejci M, Doubek M, Dusek J, Brychtova Y, Racil Z, Navratil M, Tomiska M, Horky O, Pospisilova S, Mayer J.

Ann Hematol. 2013 Oct;92(10):1397-403. doi: 10.1007/s00277-013-1790-5. Epub 2013 Jun 1.

PMID:
23728608
24.

The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus.

Mraz M, Stano Kozubik K, Plevova K, Musilova K, Tichy B, Borsky M, Kuglik P, Doubek M, Brychtova Y, Mayer J, Pospisilova S.

Leuk Res. 2013 Jul;37(7):802-8. doi: 10.1016/j.leukres.2013.03.018. Epub 2013 Apr 20.

PMID:
23608880
25.

ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Navrkalova V, Sebejova L, Zemanova J, Kminkova J, Kubesova B, Malcikova J, Mraz M, Smardova J, Pavlova S, Doubek M, Brychtova Y, Potesil D, Nemethova V, Mayer J, Pospisilova S, Trbusek M.

Haematologica. 2013 Jul;98(7):1124-31. doi: 10.3324/haematol.2012.081620. Epub 2013 Apr 12.

26.

The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab.

Panovská A, Smolej L, Lysák D, Brychtová Y, Šimkovič M, Motyčková M, Vodárek P, Lindtnerová M, Trbušek M, Malčíková J, Pospíšilová Š, Mayer J, Doubek M.

Eur J Haematol. 2013 Jun;90(6):479-85. doi: 10.1111/ejh.12106. Epub 2013 Apr 27.

PMID:
23506191
27.

The planar cell polarity pathway drives pathogenesis of chronic lymphocytic leukemia by the regulation of B-lymphocyte migration.

Kaucká M, Plevová K, Pavlová S, Janovská P, Mishra A, Verner J, Procházková J, Krejcí P, Kotasková J, Ovesná P, Tichy B, Brychtová Y, Doubek M, Kozubík A, Mayer J, Pospísilová S, Bryja V.

Cancer Res. 2013 Mar 1;73(5):1491-501. doi: 10.1158/0008-5472.CAN-12-1752. Epub 2013 Jan 21.

28.

[Febrile pancytopenia and hepatosplenomegaly as leading symptoms of visceral leishmaniasis].

Polák P, Svoboda R, Kubáčková P, Brychtová Y, Panovská A, Nohýnková E, Husa P, Freibergerová M, Pařízková R, Snelerová M, Pýchová M, Kamelander J.

Vnitr Lek. 2012 Oct;58(10):761-4. Czech.

PMID:
23121063
29.

Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.

Krejci M, Doubek M, Brychtova Y, Stehlikova O, Chovancova J, Tichy B, Francova HS, Navratil M, Tomiska M, Horky O, Pospisilova S, Mayer J.

Ann Hematol. 2013 Jan;92(2):249-54. doi: 10.1007/s00277-012-1579-y. Epub 2012 Sep 27.

PMID:
23014659
30.

Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.

Smolej L, Doubek M, Panovská A, Simkovič M, Brychtová Y, Belada D, Motyčková M, Mayer J.

Leuk Res. 2012 Oct;36(10):1278-82. doi: 10.1016/j.leukres.2012.07.005. Epub 2012 Jul 25.

PMID:
22840362
31.

Gene expression profiling of acute graft-vs-host disease after hematopoietic stem cell transplantation.

Verner J, Kabathova J, Tomancova A, Pavlova S, Tichy B, Mraz M, Brychtova Y, Krejci M, Zdrahal Z, Trbusek M, Volejnikova J, Sedlacek P, Doubek M, Mayer J, Pospisilova S.

Exp Hematol. 2012 Nov;40(11):899-905.e5. doi: 10.1016/j.exphem.2012.06.011. Epub 2012 Jul 4.

PMID:
22771791
32.

[Summary of recommendations for the diagnosis and therapy of BCR/ABL-negative myeloproliferation of the Czech Working Group for Ph-negative myeloproliferative disease (CZEMP) of the Czech Hematologic Society CLS JEP ].

Penka M, Schwarz J, Campr V, Pospíšilová D, Křen L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulíček P, Jonášová A, Kissová J, Kořístek Z, Schützová M, Vonke I, Walterová L; Czech Working Group of the Czech Hematologic Society CLS JEP.

Vnitr Lek. 2012 Feb;58(2):163-8. Czech. No abstract available. Erratum in: Vnitr Lek. 2012 Apr;58(4):308.

PMID:
22463098
33.

Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia.

Doubek M, Trbušek M, Malčíková J, Brychtová Y, Smardová J, Lochmanová J, Panovská A, Skuhrová Francová H, Mráz M, Tichý B, Sebejová L, Navrkalová V, Plevová K, Kuglík P, Mayer J, Pospíšilová S.

Leuk Lymphoma. 2012 Sep;53(9):1817-9. doi: 10.3109/10428194.2012.658794. Epub 2012 Mar 1. No abstract available.

PMID:
22263566
34.

MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia.

Mraz M, Dolezalova D, Plevova K, Stano Kozubik K, Mayerova V, Cerna K, Musilova K, Tichy B, Pavlova S, Borsky M, Verner J, Doubek M, Brychtova Y, Trbusek M, Hampl A, Mayer J, Pospisilova S.

Blood. 2012 Mar 1;119(9):2110-3. doi: 10.1182/blood-2011-11-394874. Epub 2012 Jan 10.

35.

Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.

Krejci M, Brychtova Y, Doubek M, Tomiska M, Navratil M, Racil Z, Dvorakova D, Horky O, Lengerova M, Pospisilova S, Mayer J.

Neoplasma. 2011;58(5):406-14.

PMID:
21744994
36.

Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia.

Trbusek M, Smardova J, Malcikova J, Sebejova L, Dobes P, Svitakova M, Vranova V, Mraz M, Francova HS, Doubek M, Brychtova Y, Kuglik P, Pospisilova S, Mayer J.

J Clin Oncol. 2011 Jul 1;29(19):2703-8. doi: 10.1200/JCO.2011.34.7872. Epub 2011 May 23.

PMID:
21606432
37.

Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.

Doubek M, Mayer J, Obrtlíková P, Smolej L, Cmunt E, Schwarz J, Brejcha M, Kozmon P, Pospíšilová S, Brychtová Y, Pospíšil Z, Trněný M.

Eur J Haematol. 2011 Aug;87(2):130-7. doi: 10.1111/j.1600-0609.2011.01639.x.

PMID:
21535162
38.

[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].

Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.

Vnitr Lek. 2011 Feb;57(2):189-213. Review. Czech.

PMID:
21416861
39.

Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.

Fiegl M, Falkner F, Steurer M, Zojer N, Hopfinger G, Haslbauer F, Winder G, Voskova D, Andel J, Lang A, Brychtova Y, Mayer J, Greil R, Gastl G; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia; Czech Leukemia Study Group for Life; CELL.

Ann Hematol. 2011 Sep;90(9):1083-91. doi: 10.1007/s00277-011-1192-5. Epub 2011 Feb 25.

PMID:
21350830
40.

Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL).

Panovská A, Doubek M, Brychtová Y, Mayer J.

Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):297-300. doi: 10.3816/CLML.2010.n.061.

PMID:
20709668
41.

Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.

Fiegl M, Erdel M, Tinhofer I, Brychtova Y, Panovska A, Doubek M, Eigenberger K, Fonatsch C, Hopfinger G, Mühlberger H, Zabernigg A, Falkner F, Gastl G, Mayer J, Greil R; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL.

Ann Oncol. 2010 Dec;21(12):2410-9. doi: 10.1093/annonc/mdq236. Epub 2010 May 13.

PMID:
20466745
42.

High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.

Kotaskova J, Tichy B, Trbusek M, Francova HS, Kabathova J, Malcikova J, Doubek M, Brychtova Y, Mayer J, Pospisilova S.

J Mol Diagn. 2010 May;12(3):328-34. doi: 10.2353/jmoldx.2010.090100. Epub 2010 Mar 12.

43.

[The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin].

Penka M, Schwarz J, Pavlík T, Indrák K, Doubek M, Dulícek P, Pospísilová D, Kissová J, Jonásová A, Jelínková P, Hlusí A, Schutzová M, Cerná O, Brychtová Y, Nováková L, Korístek Z, Segethová J, Vozobulová V, Hadacová I, Hochová I, Voglová J, Walterová L, Bodzásová C, Dusek L.

Vnitr Lek. 2009 Nov;55(11):I-XII. Czech.

PMID:
20017445
44.

Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.

Malcikova J, Smardova J, Rocnova L, Tichy B, Kuglik P, Vranova V, Cejkova S, Svitakova M, Skuhrova Francova H, Brychtova Y, Doubek M, Brejcha M, Klabusay M, Mayer J, Pospisilova S, Trbusek M.

Blood. 2009 Dec 17;114(26):5307-14. doi: 10.1182/blood-2009-07-234708. Epub 2009 Oct 22.

45.

[B-cell chronic lymphocytic leukaemia and the similar states].

Krejcí M, Adam Z, Pour L, Brychtová Y, Mayer J, Vorlícek J.

Vnitr Lek. 2009 Sep;55(9):746-65. Review. Czech.

PMID:
19785372
46.

[Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics].

Doubek M, Jungová A, Brejcha M, Panovská A, Brychtová Y, Pospísil Z, Mayer J; CELL, The CzEch Leukemia Study Group--for Life.

Vnitr Lek. 2009 Jun;55(6):549-54. Czech.

PMID:
19662885
47.

Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.

Doubek M, Palasek I, Pospisil Z, Borsky M, Klabusay M, Brychtova Y, Jurcek T, Jeziskova I, Krejci M, Dvorakova D, Mayer J.

Exp Hematol. 2009 Jun;37(6):659-72. doi: 10.1016/j.exphem.2009.03.004.

PMID:
19463768
48.

Autologous hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: still not out of fashion.

Doubek M, Folber F, Koristek Z, Brychtova Y, Krejci M, Tomiska M, Navratil M, Mikulasova P, Mayer J.

Ann Hematol. 2009 Sep;88(9):881-7. doi: 10.1007/s00277-009-0700-3. Epub 2009 Jan 27.

PMID:
19172272
49.

Inactivation of p53 and amplification of MYCN gene in a terminal lymphoblastic relapse in a chronic lymphocytic leukemia patient.

Stano-Kozubik K, Malcikova J, Tichy B, Kotaskova J, Borsky M, Hrabcakova V, Francova H, Valaskova I, Bourkova L, Smardova J, Doubek M, Brychtova Y, Pospisilova S, Mayer J, Trbusek M.

Cancer Genet Cytogenet. 2009 Feb;189(1):53-8. doi: 10.1016/j.cancergencyto.2008.10.003.

PMID:
19167613
50.

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities.

Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J, Stano Kozubik K, Smardova J, Brychtova Y, Doubek M, Trbusek M, Mayer J, Pospisilova S.

Leukemia. 2009 Jun;23(6):1159-63. doi: 10.1038/leu.2008.377. Epub 2009 Jan 22. No abstract available.

PMID:
19158830

Supplemental Content

Loading ...
Support Center